|
Cerebrovascular accident
|
0.310 |
Biomarker
|
group |
CTD_human |
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
|
29531354 |
2018 |
|
Cerebrovascular accident
|
0.310 |
GeneticVariation
|
group |
BEFREE |
We identified common variants near FOXF2 that are associated with increased stroke susceptibility.
|
27068588 |
2016 |
|
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
|
29531354 |
2018 |
|
Neoplasm Metastasis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
FOXF2 and FOXQ1, forkhead box transcription factor superfamily members, are encoded by neighboring genes located on human chromosome 6p25.3 and play opposite roles in epithelial-mesenchymal transition (EMT) and metastasis in basal-like breast cancer (BLBC).
|
30807702 |
2019 |
|
Neoplasm Metastasis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
The epithelial-to-osteomimicry transition regulated by FOXF2 confers a tendency on cancer cells to metastasize to bone which leads to osteolytic bone lesions.
|
31222004 |
2019 |
|
Neoplasm Metastasis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Our data identify the transcription factor Foxf2 as one of the important regulators of EMT, displaying a dual function in promoting tumor cell apoptosis as well as tumor cell migration.
|
30285803 |
2018 |
|
Neoplasm Metastasis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
The forkhead box F2 (Foxf2) gene suppresses epithelial-mesenchymal transition via the modulation of transcription of zinc finger E-box-binding homeobox 1 (Zeb1) and epithelial (E)-cadherin, thereby inhibiting tumor metastasis.
|
28829888 |
2017 |
|
Neoplasm Metastasis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
FOXF2 deficiency induced mesenchymal-epithelial transition (MET) in Huh7 cell which might facilitate the colonization of circulating tumor cells and the formation of metastasis.
|
28582850 |
2017 |
|
Neoplasm Metastasis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our previous study demonstrated that FOXF2 functions as an EMT suppressor and that FOXF2 deficiency promotes BLBC metastasis.
|
26210254 |
2015 |
|
Neoplasm Metastasis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
In this study, we further characterized the role of FOXF2 in metastasis of basal-like breast cancer (BLBC) and underlying molecular mechanisms.
|
25848863 |
2015 |
|
Neoplasm Metastasis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, we conclude that decreased FOXF2 expression indicates the early-onset metastasis and poor prognosis for patients with histological grade II and triple-negative breast cancer.
|
23620774 |
2013 |
|
Basal-Like Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Therefore, blocking the vicious cycle of the abnormal reciprocal feedback loop between FOXF2 and FOXQ1 to induce cell differentiation and restore tissue homeostasis is a promising strategy for the treatment of aggressive BLBC.-Kang, L.-J., Yu, Z.-H., Cai, J., He, R., Lu, J.-T., Hou, C., Wang, Q.-S., Li, X.-Q., Zhang, R., Feng, Y.-M.
|
30807702 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Ectopic expression of FOXF2 inhibited proliferation, colony formation, G<sub>1</sub>-S cell-cycle transition, induced apoptosis of gastric cancer cell lines, and suppressed growth of xenograft tumors in nude mice; knockdown of FOXF2 elicited opposing effects.
|
29374064 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Our data identify the transcription factor Foxf2 as one of the important regulators of EMT, displaying a dual function in promoting tumor cell apoptosis as well as tumor cell migration.
|
30285803 |
2018 |
|
Basal-Like Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
The fact that FOXF2 controls the activation of the VEGF-C/VEGFR3 signaling pathway in BLBC cells provides potential molecular diagnostic and therapeutic strategies for lymphatic metastasis in BLBC patients.
|
29409810 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Cell cycle regulatory proteins Cdk2, Cdk4/6, Cyclin D1 and Cyclin E2 were decreased in FoxF1- and FoxF2-deficient RMS tumors.
|
27425595 |
2017 |
|
Basal-Like Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
The MAZ mRNA level, particularly in combination with the FOXF2 mRNA level, may serve as a prognostic marker for BLBC patients.
|
28577976 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These findings suggest that FOXF2 has a dual role in breast tumorigenesis and functions as either a tumor suppressor or an oncogene depending on the breast tumor subtype.
|
27377963 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Using RNA interference (RNAi), we investigated the effects of FOXF2 depletion on tumor cell behavior in vitro.
|
25824262 |
2016 |
|
Basal-Like Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
However, the EMT function of FOXF2 is still required for mobility, invasiveness and anchorage-independent growth of basal-like breast cancer cells.
|
27377963 |
2016 |
|
Basal-Like Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our previous study demonstrated that FOXF2 functions as an EMT suppressor and that FOXF2 deficiency promotes BLBC metastasis.
|
26210254 |
2015 |
|
Basal-Like Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
FOXF2 deficiency enhances the metastatic ability of BLBC cells through activation of the epithelial-mesenchymal transition program, but reduces cell proliferation.
|
26070560 |
2015 |
|
Basal-Like Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
TWIST1 was negatively regulated by FOXF2 and mediated the FOXF2-regulated EMT phenotype of basal-like breast cells and aggressive property of BLBC.
|
25848863 |
2015 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Results showed that FOXF2 mRNA levels in primary breast cancer were negatively associated with tumor progression, including tumor size, number of metastatic lymph nodes, and clinical stage.
|
23620774 |
2013 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Also knock down of miR-182-5p in order to increase expression of tumor suppressor genes FOXF2, RECK and MTSS1 may be of therapeutic benefit in prostate cancer treatment.
|
23383207 |
2013 |